Sevoflurane Goes Generic and RxElite Is Up and Running!
1. RxElite has THE PRODUCT — the most widely used inhalable anesthetic in the world — AND the U.S. distribution rights for that product.
2. Sevoflurane whose Minrad trade name is Sojourn(TM) is THE modern generic anesthetic.
3. The US market is estimated to be a $400M opportunity.
4. RxElite is the exclusive commercial partner in the US for Minrad International Inc. (Minrad) (Amex: BUF – News), who announced in May that the U.S. Food and Drug Administration had given its approval to market its generic version of Sevoflurane.
5. Rx Elite is one of three distributors in the United States for Sevoflurane.
6. Rx Elite recently closed on $19.6M in financing.
7. RxElite has the distribution channel in place.
8. RxElite has agreements with over ninety percent of the U.S. market for generic drugs.
9. These agreements represent 50 of the top 75 generic drug buyers.
10. Key select customers include:
11. Hospital Purchasing Rx Elite has in place vendor contracts with the eight major GPO’s that account for ninety percent of hospital purchasing.
12. Read Recent Oppenheimer Reports on Minrad International, RxElite, and sevoflurane:
A. June 28, 2007, Oppenheimer Report
B. August 18, 2007, Oppenheimer Report
Servoflurane
You know it now!
Source: RxElite Holdings, Inc.
RxElite Holdings, Inc.
Ph: (208) 288-5550
Toll Free: (800) 414-1901
Fax: (208) 288-1191 Investor Relations
Charlie Forshee, 215-885-4981
investorrelations@rxelite.com
Segue Ventures LLCAbout RxElite Holdings, Inc.: RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause the our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
Disclosure: Pentony Enterprises LLC was compensated $18,000.00. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC,9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com.
